La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Azure Power Global a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Azure Power Global..

Azure Power Global (OTC:AZREF) Azioni, Catena delle Opzioni

Azure Power Global Ltd limited liability company incorporated in Mauritius. The company is a renewable energy developer and independent renewable power producer, and company's entire operates takes place in India itself. Company sell renewable power to customers in India on long term fixed price contracts, in many cases at prices at or below prevailing alternatives for customers. Company recognize revenue monthly from renewable energy sold to customers on a per kilowatt hour basis for the electricity supplied by the renewable power plants. It sells renewable energy based on terms in PPAs.

AZURE POWER GLOBAL LTD by Azure Power Global Limited

Azure Power Global Ltd

<ul>
<li>Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53%</li>
<li>APG808 demonstrated the potential for durable disease control in asthma with sustained FeNO decrease from baseline of 50% at 12 weeks</li>
<li>APG808's optimized formulation and potential best-in-class pharmacokinetic (PK) profile, combined with robust and sustained FeNO suppression through 12 weeks, support the potential for transformative dosing every 2-months or longer, compared to the current biweekly standard of care</li>
<li>APG808 was well tolerated with a favorable safety profile consistent with the anti-IL-4Rα class</li>
<li>Phase 1b proof-of-concept data validates Apogee's approach to designing potentially best-in-class biologics and builds on Apogee's track record of execution</li>
</ul>

Biotech

News

Health Care

General

APGE

Apogee Therapeutics Released Interim Data From Its Phase 1b Trial Of APG808, A Novel Half-life Extended IL-4Rα Antibody, In Patients With Mild-to-moderate Asthma

Vertical Aerospace ("Vertical") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) today announced it is developing a hybrid-electric vertical-take-off-and landing (VTOL) variant of its VX4 aircraft, expanding range and payload capabilities to unlock new market opportunities within the already sizable $1TR1 total addressable urban air mobility market.
&nbsp;
&nbsp;
Vertical's second-generation hybrid-propulsion system, which has been in development for 18 months at the Vertical Energy Centre
Vertical's hybrid-electric strategy builds on its all-electric VX4 and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fvertical-aerospace.com%2Fwp-content%2Fuploads%2F2024%2F11%2FVertical-Aerospace-Launches-Flightpath-2030-a-strategy-to-pioneer-electric-aviation.pdf&amp;esheet=54252992&amp;newsitemid=20250512888129&amp;lan=en-US&amp;anchor=Flightpath+2030+strategy&amp;index=1&amp;md5=4ff01c56d06d0d49334fe4ce9c9c11f4">Flightpath 2030 strategy</a>, enabling new potential applications in defence, logistics and commercial sectors including air ambulance services, which require longer range and higher payload than current eVTOL platforms can deliver.
Vertical's second-generation hybrid-propulsion system, which has been in development for 18 months at the Vertical Energy Centre, will be retrofitted into one of the company's VX4 full scale prototypes and is expected to commence flight testing in Q2 2026.

EVTL

Vertical Aerospace Unveils Hybrid Air Taxi to Boost Range, Targeting $1T Urban Air Mobility Market

<ul>
<li>Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling</li>
<li>First patient dosed in Phase 1b trial of APG777 in mild-to-moderate asthma with readout expected in 1H 2026</li>
<li>APG279 on track to initiate Phase 1b head-to-head trial vs DUPIXENT in 2025 with readout expected in 2H 2026</li>
<li>Positive interim Phase 1b readout of APG808 in patients with mild-to-moderate asthma demonstrated rapid, robust and sustained suppression of FeNO, a biomarker of Type 2 inflammation that is associated with exacerbations in asthma</li>
</ul>

Earnings

Guidance

Apogee Therapeutics Cash, Cash Equivalents And Marketable Securities Were $681.4M As Of March 31, 2025 That Supports Runway Into Q1 2028

Allot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLT#NASDAQ">ALLT</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.05) by 140 percent. This is a 166.67 percent increase over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $23.20 million which beat the analyst consensus estimate of $20.20 million by 14.85 percent. This is a 5.98 percent increase over sales of $21.89 million the same period last year.

Earnings Beats

ALLT

Allot Q1 Adj. EPS $0.02 Beats $(0.05) Estimate, Sales $23.20M Beat $20.20M Estimate

Earnings Misses

ORLA

Orla Mining Q1 Adj. EPS $0.12 Beats $0.10 Estimate, Sales $140.67M Miss $163.19M Estimate

Keybanc analyst Steve Barger upgrades Federal Signal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSS#NYSE">FSS</a>) from Sector Weight to Overweight and announces $110 price target.

Upgrades

Price Target

Analyst Ratings

Keybanc Upgrades Federal Signal to Overweight, Announces $110 Price Target

Rumors

Tech

AAPL

The Wall Street Journal Reported Apple Is Weighing Fall iPhone Price Increases; Won't Attribute Hikes to Tariffs

OrganiGram Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) reported quarterly sales of $45.70 million which beat the analyst consensus estimate of $42.28 million by 8.08 percent. This is a 63.69 percent increase over sales of $27.92 million the same period last year.

OrganiGram Holdings Q2 Sales $45.70M Beat $42.28M Estimate

Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>), a company developing electric air taxis for commercial passenger service, today announced it has successfully flown two of its aircraft simultaneously for the first time, marking another important milestone in the Company's flight testing program.
&nbsp;
&nbsp;
Two Joby air taxis (N541JX and N544JX) flying simultaneously in the skies over Marina, CA. Joby Aviation photo
The two-aircraft flight, completed in Marina, CA, on May 9, is a further demonstration of the maturity of Joby's test program, and comes just two weeks after the Company announced it had reached another testing landmark, successfully completing flights with a full transition from vertical to cruise flight, and back again, with a pilot onboard.

JOBY

Joby Aviation Flies Two Air Taxis Together for First Time, Marking Major Leap Toward Commercial Launch

EVEX

Eve Holding Q1 EPS $(0.16) Misses $(0.14) Estimate

GUIDANCE
Rockwell confirms its 2025 annual guidance as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2025 Annual Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Sales</td>
<td colspan="1" rowspan="1">$65.0M to $70.0M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross Margin</td>
<td colspan="1" rowspan="1">16% to 18%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">($0.5)M to $0.5M</td>
</tr>
</tbody>
</table>
</figure>

RMTI

Rockwell Medical Affirms FY2025 Sales Guidance of $65.00M-$70.00M vs $67.42M Est

Aurinia Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUPH#NASDAQ">AUPH</a>) affirms FY2025 sales outlook from $250.00 million-$260.00 million to $250.00 million-$260.00 million vs $257.87 million estimate.

AUPH

Aurinia Pharmaceuticals Affirms FY2025 Sales Guidance of $250.00M-$260.00M vs $257.87M Est

Century Casinos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTY#NASDAQ">CNTY</a>) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.51) by 31.37 percent. This is a 48.89 percent decrease over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $130.44 million which missed the analyst consensus estimate of $139.55 million by 6.53 percent. This is a 4.10 percent decrease over sales of $136.02 million the same period last year.

CNTY

Century Casinos Q1 EPS $(0.67) Misses $(0.51) Estimate, Sales $130.44M Miss $139.55M Estimate

Hudbay Minerals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBM#NYSE">HBM</a>) reported quarterly earnings of $0.24 per share which beat the analyst consensus estimate of $0.12 by 100 percent. This is a 41.18 percent increase over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $594.50 million which beat the analyst consensus estimate of $573.89 million by 3.59 percent. This is a 13.24 percent increase over sales of $524.99 million the same period last year.

Hudbay Minerals Q1 Adj. EPS $0.24 Beats $0.12 Estimate, Sales $594.50M Beat $573.89M Estimate

Hudbay Minerals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/HBM#TSX">HBM</a>) reported quarterly earnings of $0.24 per share which beat the analyst consensus estimate of $0.11 by 118.18 percent. This is a 50 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $594.90 million which beat the analyst consensus estimate of $521.50 million by 14.07 percent. This is a 13.32 percent increase over sales of $524.99 million the same period last year.

TSX:HBM

Hudbay Minerals Q1 Adj. EPS $0.24 Beats $0.11 Estimate, Sales $594.90M Beat $521.50M Estimate

US Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEG#NASDAQ">USEG</a>) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.05) by 100 percent. This is a 73.68 percent increase over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $2.19 million which missed the analyst consensus estimate of $3.50 million by 37.41 percent. This is a 59.32 percent decrease over sales of $5.39 million the same period last year.

USEG

US Energy Q1 GAAP EPS $(0.10) Misses $(0.05) Estimate, Sales $2.19M Miss $3.50M Estimate

Rockwell Medical Q1 2025 Adj. EPS $(0.01) Beats $(0.04) Estimate, Sales $18.91M Beat $16.77M Estimate

Aurinia Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUPH#NASDAQ">AUPH</a>) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.10 by 60 percent. This is a 328.57 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $62.47 million which beat the analyst consensus estimate of $61.54 million by 1.51 percent. This is a 24.18 percent increase over sales of $50.30 million the same period last year.

Aurinia Pharmaceuticals Q1 EPS $0.16 Beats $0.10 Estimate, Sales $62.47M Beat $61.54M Estimate

Dole (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOLE#NYSE">DOLE</a>) reported quarterly earnings of $0.35 per share which missed the analyst consensus estimate of $0.39 by 10.26 percent. This is a 18.6 percent decrease over earnings of $0.43 per share from the same period last year. The company reported quarterly sales of $2.10 billion which beat the analyst consensus estimate of $2.05 billion by 2.41 percent. This is a 1.04 percent decrease over sales of $2.12 billion the same period last year.

DOLE

Dole Q1 Adj. EPS $0.35 Misses $0.39 Estimate, Sales $2.10B Beat $2.05B Estimate

Needham analyst John Todaro maintains Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Buy and lowers the price target from $330 to $270.

Comments

Azure Power Global

Azure Power Global (AZREF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO